Introduction
Privacy and confidentiality are core principles of a safe patient-physician relationship. Over a lifetime, important information about medical history, medication use, diagnostic tests, and therapies is registered in patients' medical records. Medical information is considered to be a special category of data, as for most patients the disclosure of the fact that a person suffers from progressive heart failure, a psychiatric disorder or cancer is a far more sensitive aspect of their personal life than for instance the make of car they drive. 1 While in the past, data used to be registered and stored in the form of paper records, nowadays data are digitally collected and stored in Electronic Patient Records (EPRs) and easy accessible. Healthcare providers handle large amounts of digital patient data in such records, and these patient data are an essential part of current healthcare. [2] [3] [4] Privacy and data protection are an important and ongoing concern in general but also in healthcare. Recently, multiple healthcare providers in the USA have been the target of hackers stealing personal patient data with more than 1 million patients affected. 5 Furthermore, in 2016 Hospital Trusts within the National Health Service (NHS) in England and Scotland were hit by a large ransomware attack, which resulted in locking computers and demands for payment for them to be unlocked. 6 The general concern about privacy has been articulated in the new European law on privacy, the 'General Data Protection Regulation' (GDPR) which has come into force on 25 May 2018. These new European data protection rules will have consequences for healthcare. Many healthcare providers do not appear to be fully aware of the new relevant legislation and the implications of using patient data for secondary purposes as monitoring of quality and medical data research. This may also apply to European quality-of-care registries, which use data from EPR's for performance as well as outcome measurements of hospitals and medical data research. 7 Not being aware of the new legislation could lead to risks, varying from reputational damage to financial loss due to the high relating fines from national supervisory authorities, but it may also have a negative impact on the patient-physician relationship and ultimately lead to losing the public trust and patients being reluctant to participate. In this review, the main implications of the new European data protection rules are for quality-of-care registries in Europe are examined. First, three quality-of-care registries in the field of cardiology and cardiothoracic surgery in Europe are discussed. Second, a general overview of the European legal framework (relevant data protection and privacy legislation) applying to quality-of-care registries is provided. Third, the specific implications of the legal framework on quality-of-care registries are discussed.
Quality-of-care registries in cardiology and cardiothoracic surgery
A quality-of-care registry is usually an independent organization maintaining a database containing information about a patient population with a specific disease, type of care or complication, or a combination of these, that is used to measure, improve, and report the quality of the care provided. The registry also organizes the processes to select and define the parameters. Monitoring quality of care primarily involves collecting, analysing, and publishing specific patient data and results of the care delivered. Describing these in comparable patients using pre-specified variables, relationships, and comparisons can give insights into how to improve the quality of care. 8 Healthcare providers collect data by entering data into a portal, by automatically linking EPRs, or by delivering files with data. In general, participating healthcare providers are responsible for data collection and registration. After the data collection phase, the data files are securely stored after being encrypted by the registry. Subsequently, these aggregated data are analysed and adjusted by the agency that is responsible for the registration, then prepared for publication. The results are reported back to the healthcare providers themselves but also to the public and to other specific stakeholders, such as healthcare insurance companies, regulatory agencies, and patient's groups. When combining different databases, a third trusted party acts as an intermediary who links encrypted data with personal identifiable data (e.g. date of birth). To ensure the quality of the data analysis, registries comply to international standard frameworks for information security, such as NEN 7510 (for securing of data), 7512 (for exchanging data), and 7513 (for logging and access to data). 9 NEN are agreements made by market parties facilitated by the Dutch Normalisation Institute. Three national quality registries in cardiology and cardiothoracic surgery in the Netherlands, Sweden, and UK will be described. For each registry, the handling of privacy and informed consent is described. An overview is provided in Table 1 .
National registries in cardiovascular disease-The Netherlands
The Netherlands Heart Registration (Nederlandse Hart Registratie, NHR) is the major cardiovascular quality-of-care registry in the Netherlands. 10 The aim of the NHR is to monitor and improve quality of care of heart disease for the individual patient by collecting and analysing patient data, reporting relevant outcome indicators in yearly publicly accessible reports, and carrying out medical data research.
The registry (a merger of three national registries) was initiated in 2017 by healthcare providers and is funded by participating departments. 11 Outcome indicators for cardiothoracic surgery, acute coronary syndromes, percutaneous coronary intervention, transcatheter heart valve implantations, ablation of atrial fibrillations, and device implantations are included. The NHR has a NEN-7510 certification. Encryption is used to pseudomize personal data. 12, 13 Participating health care providers are responsible for data collection and registration and remain the owners of these data. 14 
National registries in cardiovascular disease-Sweden
The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) is a Swedish quality-ofcare registry that reports the outcome of hospitalized patients with respect to acute coronary syndrome and coronary or valvular intervention. 15 The aims of SWEDEHEART are to support development of evidence-based therapy in heart disease, to register changes in quality of care over time within a hospital and in comparison with other hospitals, to form the basis for scientific research on heart disease (coronary artery disease and valve intervention) and to contribute to reduced mortality and morbidity in patients while improving cost-effectiveness of patient care. There is the possibility of merging the SWEDEHEART database with other national registries to offer complete follow-up of patients with heart disease. The registry (a merger of four national registries) was initiated in 2010 and is publicly funded (by the national societies of cardiology and thoracic surgery and the Swedish state). Every hospital in Sweden takes part in the registry and outcome indicators for coronary angiography, catheter-based interventions, and heart surgery are collected.
National registries in cardiovascular disease-Great Britain
In the UK, the National Institute for Cardiovascular Outcomes Research (NICOR) is the quality-of-care registry for heart disease that collects the outcomes of patients in England, Wales, and Northern Ireland. The aim of NICOR is to collect data and produces analyses to monitor and improve quality of care and outcomes of heart disease. NICOR encourages the use of data for scientific research and can link data to other national data sets.
The registry consists of six national audits and two registries and is publicly funded by the NHS and the national societies of cardiology and thoracic surgery. Clinical information about cardiovascular patients is collected by hospitals across the UK and stored in secure databases. Only in the Myocardial Ischaemia National Audit Project (one of the six national audits, the MINAP registry), more than 1 300 000 patient records have been included. The first MINAP report was published in 2011. NICOR stores and analyses information in a secure environment. NICOR never publishes information that could lead to identification of individual patients, because patient records are cleaned and pseudonymized. Only appropriate data controllers are able to see identifiable patient data. Informed consent is not asked.
Summary
Although the specifics of the saved personal data and omission of identifiable data differ somewhat between these three described European registries, they all secure data by pseudomization and use privacy-enhancing techniques. 16 None of the registries ask the patient for informed consent to use their data in the quality-of-care registry. All of these registries carry out medical data research using the collected patient data, although the output varies considerably between the different registries.
Compared to the number of scientific publications from the Swedish (65 scientific publications in 2017) and British registry (estimated 13 scientific publications in 2017), the Dutch cardiovascular registry only published 1 scientific article in 2017.
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Legal framework
Requirements following from international and European regulations
Quality-of-care registries collect and process large amounts of patient data, not only to use them for monitoring simply the quality of care within a single institution but also to improve quality of healthcare (amongst others by publishing data analyses) and to stimulate medical data research. To facilitate this type of research, long-term storage and data linkage are pre-requisites. 19 The latter is significant because the legal provisions applying to setting up and using patient data purely for quality monitoring and the provisions for carrying out medical data research (and setting up research databases) are not the same.
The main rules concerning patient data are provided by binding legislation from the European Union (EU). From 1995 until 2018, the governing EU legislation was the European Privacy Directive (Directive 95/46/EC) on processing of personal data. 20 In 2012, the 1 The GDPR does not require implementation and is directly applicable in all member states to ensure a consistent and high level of protection of individuals. The GDPR makes it possible for national supervisory authorities to impose high fines to institutions in case of violation. The leading principle of the GPDR, as included in article 9, is that the processing of sensitive personal data is prohibited, but it is allowed in specific cases set out in the GDPR. Proving explicit informed consent is an example of such an exception as well as data processing for health care purposes.
When patient data are used for monitoring quality of care within healthcare institutions, article 9, paragraph 2 sub i of the GPDR is applicable. It allows collection and use of personal data to manage healthcare systems or to guarantee high standards of quality of care. 21 However, if quality-of-care data are used for medical data research, a stricter legal regime for the processing of the collected data should be taken into account. The main rules are provided by the same binding legislation from the EU, the GDPR. 22 From article 9, paragraph 2 sub i GDPR, it follows that collection and use of personal data for medical data research is allowed when this is done in accordance with the principle of proportionality and the purpose of the research while appropriate measures have been taken to protect the rights of the individual subjects. 21 Appropriate measures include collecting the smallest amount of data necessary for research and the anonymization of data when possible. The full-text of the relevant articles of the GDPR mentioned before are shown in Table 2 . EU-law is directly applicable in the member states. In some fields, like collecting and processing personal data for medical data research, the GDPR does not regulate in detail the exact responsibilities of healthcare providers and researchers. In this case, non-binding rules developed by the Council of Europe and the European Science Foundation could provide further guidance. The main principles are that non-anonymous or identifiable medical data may only be collected and analysed, if this is necessary for carrying out the research and if the data subjects have given their informed consent. However, where it would be unrealistic to seek the individual's consent, personal data may still be collected and used, provided that certain conditions are met. One of these conditions is that the patient knows Processing of personal data shall be lawful only if and to the extent that at least one of the following applies; a. the data subject has given consent to the processing of their personal data for one or more specific purposes; ? b. processing is necessary for compliance with a legal obligation to which the controller is subject; c. processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller; (paragraph 1b and 1d have been left out) Article 9 Processing of special categories of personal data
Paragraph 1
The processing of personal data, revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, trade-union membership, and the processing of genetic data, biometric data in order to uniquely identify a person or data concerning health or sex life and sexual orientation shall be prohibited.
Paragraph 2a
Paragraph 1 shall not apply if the data subject has given explicit consent to the processing of those personal data for one or more specified purposes, except where Union law or Member State law provide that the prohibition referred to in paragraph 1 may not be lifted by the data subject.
Paragraph 2i
Paragraph 1 shall not apply if processing is necessary for archiving purposes in the public interest, or scientific and historical research purposes or statistical purposes in accordance with Article 83(1) based on Union or Member State law which shall be proportionate to the aim pursued, respect the essence of the right to data protection and provide for suitable and specific measures to safeguard the fundamental rights and the interests of the data subject.
Article 83 Safeguards and derogations for the processing of personal data for archiving purposes in the public interest, or scientific and historical research purposes or statistical purposes
Paragraph 1
Processing of personal data for archiving purposes in the public interest, or scientific and historical research purposes or statistical purposes, shall be subject to in accordance with this Regulation appropriate safeguards for the rights and freedoms of the data subject. These safeguards shall ensure that technical and organizational measures are in place in particular in order to ensure the respect of the principle of data minimization. These measures may include pseudonymization, as long as these purposes can be fulfilled in this manner. Whenever these purposes can be fulfilled by further processing of data which does not permit or not any longer permit the identification of data subjects these purposes shall be fulfilled in this manner. about the possible use of his or her data for medical data research (right to be informed on a general level) and has not objected to this (right to opt-out). 23 Requirements following from previous existing laws
In the Netherlands, according to the Dutch law on Quality, Complaints, and Disputes in Healthcare (Wet kwaliteit, klachten en geschillen zorg), it is considered an obligation of each healthcare institution to collect and register quality-of-care patient data and to use these for monitoring, assessing, and improving the quality of the care provided to patients. 24 The latter law contains no specific requirements on the protection of patient data. As mentioned before, in the Dutch cardiovascular quality-of-care registry (NHR), participating hospitals are responsible for data collection and registration and remain the owners of these data.
14 When quality-of-care data are used for medical data research purposes, apart from the GDPR and its additional provisions on a national level, the Medical Treatment Contract Act (Wet op Geneeskundige Behandelovereenkomst, referred to as WGBO, a section of the Dutch Civil Code) is particularly relevant because this law contains specific rules on data processing for medical data research. The main requirement is patient consent (Article 7: 457 Civil Code). However, when it is reasonably not possible (patient is deceased or untraceable) or feasible (large amount of patients, large chance of non-response) to obtain consent the requirement for consent may be put aside. Then, data may only be collected from patient records if they have been pseudonymized in advance. In the event of a 'consent-waiver', three additional conditions need to be met. First, the research project should serve a public interest. Second, the research could not be carried out without the data concerned. Third, the data subject is informed about the possible use of data for research projects and has not explicitly opposed to this. In the Netherlands, the Data Protection Authority (Autoriteit Persoonsgegevens) is the national supervisory authority on the processing of personal data by healthcare providers. 25 The Dutch DPA can, similar to other EU supervisory agencies, impose high fines if the law and its legal requirements are violated. In Sweden, all quality registries are regulated by the Swedish Patient Data Act (2008: 355). 26 According to this act, caregivers are allowed to use personal data entered in a registry for the primary purpose of developing and securing the quality of care. Before personal data are entered in a registry, the responsible authority has to inform the patient. The patient may oppose registration, but the law does not impose a requirement of any (signed) consent from the individual. 27 When using personal data for medical data research, the Ethical Review Act (2003: 460) is of concern. According to section 3, covering research based on registries, an ethical review whether informed consent is needed is requested if the research includes the processing of sensitive personal data (as defined by the Personal Data Act).
In the UK, the GDPR is implemented by the Data Protection Act. This legislation continues the operation of pre-existing regulations that set more specific rules realting to the processing of NHS patient data. In particular, this includes regulations which control the use of confidential patient data without informed consent in circumstances where obtaining consent would not be reasonably practicable. Under these regulations, patient data may be processed for medical purposes (like preventative medicine, medical diagnosis, and treatment and social care services) or for improving quality of healthcare. 28 However, processing may only be carried out for medical data research without informed consent, provided it has been approved by the Health Research Authority's Confidentiality Advisory Committee (CAG) and by a research ethics committee. 29 In making their determination the CAG will consider, among other factors, whether informed consent could reasonably be obtained, whether identifiers could be removed, or, whether the public interest in disclosure of information for medical data research outweighs the breach of patient confidentiality. It is this 'Section 251' mechanism, that enables registries as NICOR to process patient data without informed consent and that sets aside the legal obligation of confidentiality in such circumstances. Medical data research still requires a lawful basis under the GDPR and the other principles of data protection still apply, including that transparency information is provided and safeguards implemented. Individual patients retain the right to opt-out for research. In May 2018, a new national data opt-out programme was introduced to enable patients to opt-out of their confidential patient data being used for medical data research and planning (which includes all uses beyond individual care).
30
Implications for quality-of-care registries
The registries in the field of cardiology and cardiothoracic surgery described before not only use patient data for monitoring the quality of care within a single institution but also to improve quality of healthcare (amongst others by publishing data analyses) and to stimulate medical data research. As pointed out before, the rules for using data for medical data research are stricter than for purely monitoring quality. In most jurisdictions, based on the GDPR, one of the most important difference between to the two legal regimes is that patients have control over the use of their data for medical data research-in the form of an opt-in or opt-out possibility-while this position is absent in the context of data processing for quality of care monitoring. One means of 'escape' from the stricter rules governing the use of medical data for research would be to collect and use truly anonymous data, because in that situation data protection and privacy legislation do not apply. Anonymized data are no longer considered personal data in the context of the GDPR and national data protection legislation and handling those data is considered not to interfere with the privacy of the participating patients. 31 Registry data could only be considered truly anonymous if disproportionate effort is required to link the data to identifiable patients. The best practices for complete anonymization of data in clinical trials could also be used for complete anonymization of data in quality-of-care registries. Data could be classified into either direct identifiers or indirect identifiers, where direct identifiers (like name and initials, address including postal code) have a high risk of identifying a patient and indirect identifiers (like rare treatment, place of birth) could possibly lead to identification. 32 To anonymize a data set, it is advised in the literature to remove direct identifiers and to remove certain indirect identifiers (depending on the risk, e. 32 Although in many quality-of-care registries, data are pseudonymized by using privacy-enhancing techniques, the data contained in the described cardiology and cardiothoracic surgery registries are not truly anonymous and therefore do not escape from the consequences of the privacy and data protection legislation. First, somebut not all-identifiable data are omitted. For example, if a 87-year patient undergoes a specific, not so common procedure at this age (e.g. a coronary artery bypass grafting including mitral valve replacement), data could still be retrieved to identify this individual patient, although date of birth has been omitted in the database. Secondly, the source of the data is not deleted at the time of data collection (hospitals have even an obligation to store patient data in the EPRs for a fixed period of time). Since it is difficult-but with reasonable effort not impossible-to trace data back to individual patients, the data in these registries should be considered as pseudonymized and not anonymized.
A point of attention is that when, as a consequence of the GDPR, informed consent is introduced for these registries, consent bias could be introduced. This bias could be substantial as consenters can be systematically different from patients who do not consent. 34, 35 Not informing patients could also lead to consent bias if the negative impact on the patient-physician relationship leads to losing the public trust and patients being reluctant to participate. In the UK, the rules for collecting and using patient data for quality-of-care registries seem to leave room for an opt-out right for patient, without informed consent. In the Netherlands, the rules are more stringent. In principle, informed consent of patients should be obtained for using their data for medical research. The law leaves room for exceptions if research would become impossible or infeasible. In Sweden, an ethical review whether informed consent is needed is requested if the research includes the processing of sensitive personal data.
Conclusion
It is beyond discussion that quality-of-care registries improve quality of healthcare and should be facilitated and encouraged. 11 Patient data stored in these registries are often used for medical data research. This fact has important consequences for health care providers who provide patient data and for parties holding quality-of-care registries. Unless the personal data collected for and stored in these registries are completely anonymized (the standards for anonymization are strict), they fall within the scope of data protection law and regulations. Application of the GDPR, that came into force in the EU member states on 25 May 2018, implies that such data, in principle, may only be used for medical data research purposes after informing patients and obtaining their explicit consent. Some national jurisdictions provide the necessary room for exceptions (opt-out system) when research would be disproportionally hampered.
Informing patients and obtaining their explicit consent requires considerable effort of healthcare providers although developments in information and communication technology (ICT) could make it increasingly more easy to implement such procedures. Also, by doing so, healthcare providers invest in a trustworthy patient-physician relationship and they open new possibilities for researchers, such as the linking of international medical databases for future research.
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